Discordance between the results and conclusions of ICON7

The Lancet Oncology

Volumn 16, Issue 13, 2015, Pages e478-

  Gyawali, Bishal ^a   Shimokata, Tomoya ^a   Ando, Yuichi ^a  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVAL; EVIDENCE BASED MEDICINE; HUMAN; LETTER; OVARY CANCER; OVERALL SURVIVAL; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; FEMALE; OVARIAN NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 84953708242     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00283-1     Document Type: Letter

References (8)

1. Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 2015, 16:928-936.
2. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 2014, 32:1302-1308.
3. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012, 30:2039-2045.
4. Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 2013, 14:1020-1026.
5. Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2014, 15:396-405.
6. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011, 365:2484-2496.
7. Witteveen P, Lortholary A, Fehm T, et al. Late breaking abstract: final overall survival (OS) results from AURELIA, an open-label randomised phase III trial of chemotherapy (CT) with or without bevacizumab (BEV) for platinum-resistant recurrent ovarian cancer (OC). Eur J Cancer 2013, 49(suppl 3):S3-S4.
8. Coleman R, Brady M, Herzog T, et al. A phase III randomised controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (GOG-0213). Gynecol Oncol 2015, 137(suppl 1):3.